for medical use
of FUTsIS medicine
the Trade name
Mezhdunarodnoye the unlicensed
name Flukonazol Lekarstvennaya a form
of the Tablet of 100 mg, 150 mg and 200 mg
One tablet contains
active agent – a flukonazol of 100 mg, 150 mg, or 200 mg,
excipients: microcrystalline cellulose, lactoses monohydrate, K 30 povidone, talc, magnesium stearate, sodium of starch glikolit, sodium of a kroskarmelloz, isopropyl alcohol.
tablets, White, round with slanted edges, with the line of a break on one party (for dosages of 100 mg, 150 mg and 200 mg).
Antifungal means of system use. Triazole derivatives.
The ATX J02A C01 code
Pharmacokinetics Later properties of intake flukonazol is well soaked up, the general bioavailability – 90%. The concomitant use of food does not influence absorption of drug at intake. Concentration in plasma reaches peak in 0.5-1.5 h after reception of a flukonazol on an empty stomach, and elimination half-life makes about 30 h. Concentration in plasma is proportional to a dose. 90% of equilibrium concentration are reached by 4-5th day after the beginning of therapy (at multiple dose of drug once a day).
Linking with proteins – low (11-12%). Flukonazol well gets into all liquids of an organism.
Drug is removed, generally by kidneys, about 80% of the entered dose are found in urine in not changed look. The clearance of a flukonazol is proportional to clearance of creatinine. The circulating metabolites are not found.
Flukonazol, triazolny antifungal means, is selection inhibitor of synthesis of sterols in a cell of mushrooms, shows activity in the infections caused:
– Candida spp., including generalized candidiasis
– Cryptococcus neoformans, including intracranial infections
– Microsporum spp.
– Trychoptyton spp.
– Blastomyces dermatitides
– Coccidioides immitis
– Histoplasma capsulatum
Flukonazol has high specificity concerning the fungal enzymes dependent on cytochrome P – 450.
– a cryptococcosis, including cryptococcal meningitis and infections of other localization (for example, lungs, skin), including at patients with the normal immune response and patients with AIDS, recipients of transplanted organs and patients with other forms of an immunodeficiency, maintenance therapy for the purpose of prevention of a recurrence of a cryptococcosis at patients with AIDS.
– generalized candidiasis, including a kandidemiya, disseminate candidiasis and other forms of an invasive candidosis infection, such as infections of a peritoneum, endocardium, eyes, respiratory and uric ways, including at the patients with malignant tumors who are in intensive care units and receiving cytotoxic or immunosuppressive means and also at patients with other factors contributing ment of candidiasis
– candidiasis of mucous membranes, including mucous mouth and throat, a gullet, noninvasive bronchopulmonary infections, a kandiduriya, the skin and mucous and chronic atrophic candidiasis of an oral cavity (connected with carrying dentures), including at patients with normal and suppressed immune function, prevention of a recurrence of oropharyngeal candidiasis at patients with AIDS
– genital candidiasis, acute or recurrent vaginal candidiasis, prevention for the purpose of reduction of frequency of a recurrence of vaginal candidiasis (3 and more episodes a year), a candidosis balanitis
– prevention of fungal infections at the patients with malignant tumors predisposed to such infections as a result of cytotoxic chemotherapy or radiation therapy
– skin mycoses, including mycoses of feet, bodies, inguinal area, a chromophytosis, an onychomycosis and skin candidosis infections
– deep endemic mycoses at patients with normal immunity, a coccidioidomycosis, a paracoccidioidomycosis, a sporotrichosis and histoplasmosis.
The route of administration and doses
Use for adults
In cryptococcal meningitis and cryptococcal infections of other localization in the first day usually appoint 400 mg, and then continue treatment in a dose of 200-400 mg once a day. Duration of treatment of cryptococcal infections depends on presence of clinical and mycologic effect, in cryptococcal meningitis the treatment is usually continued at least by 6-8 weeks.
The recommended Futsis’s dosage for prevention of a recurrence of cryptococcal meningitis at patients with AIDS 200mg/days.
At a kandidemiya, disseminate candidiasis and other invasive candidosis infections the dose usually makes 400 mg in the first day, then on 200 mg/days. Depending on expressiveness of clinical effect the dose can be increased up to 400 mg/days.
Duration of therapy depends on clinical and mycologic effect.
In oropharyngeal candidiasis in the first day drug is usually appointed on 200 mg, then continue 100 mg once a day. Treatment is continued within 2 weeks to reduce recurrence probability.
In the atrophic oral candidiasis connected with carrying dentures, drug usually appoint in a dose 50 mg within 14 days in combination with local antiseptics for processing of a prosthesis once a day.
In other candidosis infections of mucous membranes (except for genital candidiasis, see below), for example, an esophagitis, noninvasive bronchopulmonary infections, a kandiduriya, skin candidiasis the effective dose usually makes 50-100 mg/days lasting treatment of 14-30 days.
For prevention of a recurrence of oropharyngeal candidiasis at patients with AIDS after end of a full course of primary therapy Futsis can be appointed on 150 mg once a week.
In vaginal candidiasis appoint once inside in a dose 150 mg. For prevention of vaginal candidiasis it is possible to use drug in a dose 150 mg once a month. Duration of therapy is determined individually, it varies from 4 to 12 months.
In a candidosis balanitis Futsis appoint once in a dose 150 mg inside.
For prevention of fungal infections at patients with malignant tumors the recommended Futsis’s dose makes 50-400 mg depending on degree of risk of developing a fungal infection once a day. For patients with high risk of a generalized infection, for example, from expressed or it is long the remaining neutropenia, the recommended dose makes 400 mg once a day.
In skin infections, including mycoses of feet, smooth skin, inguinal area, the recommended dose makes 150 mg once a week or 50 mg once a day. Therapy duration usually is 2-4 weeks, however in mycoses of feet longer therapy can be required (up to 6 weeks).
In a chromophytosis the recommended dose makes 300 mg once a week within 2 weeks, some patients need the third dose of 300 mg a week while for some patients it is accorded rather single welcome of 300-400 mg. The alternative scheme of treatment is use of drug on 50 mg within 2-4 weeks once a day.
In an onychomycosis the recommended dose makes 150 mg once a week. Treatment should be continued before full emergence of a healthy nail plate. Repeated growth of nails on fingers of hands and feet usually requires 3-6 months and 6-12 months according to. However, growth rate can vary over a wide range at different people and also depending on age. After successful treatment it is long the remaining persistent infections sometimes change of a shape of nails is observed.
In deep endemic mycoses the use of drug in a dose of 200-400 mg/days can be required. Duration of therapy is determined individually.
Use for children
As well as in similar infections at adults, duration of treatment depends on clinical and mycologic effect.
In candidiasis of mucous membranes the recommended Futsis’s dose from 7 years makes 3 mg/kg/days. In the first day for the purpose of faster achievement of constant equilibrium concentration the shock dose of 6 mg/kg can be appointed.
For treatment of generalized candidiasis and a cryptococcal infection the recommended dose makes 6-12 mg/kg/days depending on disease severity.
For prevention of fungal infections at patients with malignant tumors at which risk of developing an infection is connected with the neutropenia developing as a result of cytotoxic chemotherapy or radiation therapy drug is appointed on 3-12 mg/kg/days depending on expressiveness and duration of preservation of the induced neutropenia.
Use for elderly people
in the absence of symptoms of a renal failure drug is appointed in a usual dose. The patient with a renal failure (clearance of creatinine & lt, 50 ml/min.) the dose of drug is adjusted as it is described below.
Use for patients with a renal failure
At single dose of change of a dose is not required. At patients with a renal failure at repeated use of drug it is necessary to enter originally a shock dose from 50 mg to 400 mg then the daily dose (depending on the indication) is established according to the following table:
Clearance of creatinine (ml/min.)
Percent of the recommended dose
50 ≤50 (without dialysis)
of 100% after each dialysis
– a headache, dizziness, spasms, change of taste
– nausea, vomiting, an abdominal pain, a meteorism, diarrhea, dyspepsia
– hepatotoxicity, including exceptional cases with a lethal outcome
– increase in level of alkaline phosphatase, bilirubin, serumal level of aminotransferases (ALT and nuclear heating plant), increase in level of cholesterol and triglycerides in plasma, a hypopotassemia
– an abnormal liver function, hepatitis, hepatocellular necrosis, jaundice
– rash, an alopecia, exfoliative skin diseases, including
Stephens’s syndrome – Johnson and a toxic necrolysis of epidermis
– a leukopenia, including a neutropenia and an agranulocytosis, thrombocytopenia
– an anaphylaxis (including a Quincke’s disease, a face edema, urticaria, an itching)
– increase in an interval of QT at the ECG, blinking/trembling of ventricles
At patients with AIDS or cancer, at treatment by Futsis and similar drugs, was observed changes of indicators of blood, function of kidneys and a liver, however the clinical value of these changes and their communication with treatment are not established.
– hypersensitivity to a flukonazol, other components of drug or azolny substances with similar to a flukonazol structure
– a concomitant use of a terfenadin during repeated use of a flukonazol in a dose of 400 mg/days and more
– simultaneous use of a tsizaprid
– pregnancy and the period of a lactation
– children’s age up to 7 years
Disturbance of indicators of function of a liver against the background of use of a flukonazol, appearance of rash against the background of use of a flukonazol for patients with a superficial fungal infection and invasive/system fungal infections, simultaneous use of a terfenadin and flukonazol in a dose less than 400 mg/days, potentially pro-arrhythmic states at patients with multiple factors of risk (organic heart diseases, disturbances of electrolytic balance and the accompanying therapy contributing to the development of similar disturbances).
Flukonazol, at simultaneous use with warfarin, increases a prothrombin time (by 12%) in this connection, development of bleedings is possible (hematomas, bleedings from a nose and digestive tract, a hamaturia, a melena). At the patients receiving coumarinic anticoagulants it is necessary to control a prothrombin time constantly.
At simultaneous use in a flukonazol with azithromycin of the significant pharmacokinetic interaction between both drugs it is not established.
Benzodiazepines (short action): after midazolam intake, flukonazol significantly increases concentration of midazolam and psychomotor effects, and this influence is more significant after reception of a flukonazol inside, than at its use intravenously. In need of the accompanying therapy by benzodiazepines of the patients accepting flukonazol it is necessary to observe for the purpose of a possible dose decline of benzodiazepine.
At patients with a transplantirovanny kidney, use of a flukonazol in a dose of 200 mg/days leads to slow increase in concentration of cyclosporine. However, at multiple dose of a flukonazol in a dose of 100 mg/days of change of concentration of cyclosporine at recipients of marrow it was not observed. At simultaneous use of a flukonazol and cyclosporine it is recommended to monitorirovat concentration of cyclosporine in blood.
Repeated use of Hydrochlorthiazidum along with flukonazoly leads to increase in concentration of a flukonazol in plasma for 40%. The effect of such degree of manifestation does not demand change of the mode of dosing of a flukonazol from the patients receiving at the same time diuretics.
At simultaneous use of the combined oral contraceptives with flukonazoly in a dose of 50 mg of significant effect on the level of hormones it is not established.
Simultaneous use of a flukonazol and Phenytoinum can be followed by clinically significant increase in concentration of Phenytoinum. In case of need simultaneous use of both drugs, it is necessary to control concentration of Phenytoinum and as appropriate to correct its dose for the purpose of ensuring therapeutic concentration in serum.
Simultaneous use of a flukonazol and rifabutin can lead to increase in serumal concentration of the last. At simultaneous use of a flukonazol and rifabutin, uveitis cases are described. The patients who are at the same time receiving rifabutin and flukonazol need to be observed carefully.
At the patients who are at the same time accepting rifampicin it is necessary to consider expediency of increase in a dose of a flukonazol.
The concomitant use of oral drugs of sulphonylurea and a flukonazol leads to increase in elimination half-life of drugs of sulphonylurea (chlorpropamide, glibenclamide, a glipizid and tolbutamide). Sick diabetes it is possible to appoint combined use of a flukonazol and oral drugs of sulphonylurea, but at the same time it is necessary to consider a possibility of development of a hypoglycemia.
Simultaneous use of a flukonazol and takrolimus leads to increase in serumal concentration of the last. Nephrotoxicity cases are described. The patients who are at the same time accepting takrolimus and flukonazol should be observed carefully.
At simultaneous use of azolny antifungal means and a terfenadina developing of serious arrhythmias as a result of increase in an interval of QT is possible. At reception of a flukonazol in a dose of 200 mg/days of increase in an interval of QT it is not established, however, use of a flukonazol in doses of 400 mg/days and causes significant increase in concentration of a terfenadin in plasma above. The concomitant use of a flukonazol in doses of 400 mg/days and more with terfenadiny is contraindicated. Treatment flukonazoly in doses less than 400 mg/days in combination with terfenadiny should be carried out under careful control.
Simultaneous use of a flukonazol and theophylline leads to increase in serumal concentration of the last. When assigning a flukonazol it is necessary for the patients accepting theophylline in high doses, to control concentration of theophylline and, if necessary, to correct therapy as appropriate.
At simultaneous use of a zidovudine with flukonazoly increase in concentration of a zidovudine which is probably caused by decrease in metabolism of the last is noted. The patients receiving such combination should be observed for the purpose of identification of side effects of a zidovudine.
Simultaneous use of a flukonazol with astemizoly or other drugs which metabolism is carried out by the system of P450 cytochrome can be followed by increase in serumal concentration of these means.
Patients should be observed carefully.
Single or multiple dose of a flukonazol
In a dose of 50 mg does not influence metabolism of antipyrine at their concomitant use.
The listed interactions are established at repeated use of a flukonazol, interactions with medicines as a result of single dose of a flukonazol are not known.
In rare instances use of a flukonazol was followed by toxic changes of a liver, including with a lethal outcome, mainly at patients with serious associated diseases.
Hepatotoxic action of a flukonazol usually was reversible, its signs disappeared after the therapy termination. Patients at whom during treatment by Futsis indicators of function of a liver are broken need to be observed for the purpose of identification of signs of damage of a liver. At emergence of clinical signs or symptoms of damage of a liver which can be connected with use of a flukonazol, drug should be cancelled.
Futsis in rare instances can cause anaphylactic reactions.
During treatment by Futsis at patients exfoliative skin reactions, such as Stephens’s syndrome – Johnson and a toxic epidermal necrolysis in rare instances developed. Patients with AIDS are more inclined ment of heavy skin reactions at use of many drugs. At emergence in the patient during treatment of a superficial fungal infection of rash which can be connected with Futsis’s use, drug should be cancelled. At appearance of rash in patients with their invasive/system fungal infections it is necessary to observe and cancel carefully Futsis at emergence of bullous defeats or a mnogoformny erythema.
Futsis can cause increase in an interval of QT at the ECG. At use Futsis increase in an interval of QT and blinking/trembling of ventricles noted very seldom at seriously sick with multiple factors of risk, such as organic heart diseases, disturbances of electrolytic balance and the accompanying therapy contributing to the development of similar disturbances. Therefore such patients with potentially pro-arrhythmic states should apply Futsis with care.
Patients with diseases of a liver, heart and kidneys before Futsis’s use are recommended to consult with the doctor. At Futsis’s use 150 mg concerning vaginal candidiasis the patients have to be warned that improvement of symptoms is usually observed in 24 h, but their total disappearance sometimes requires several days. At preservation of symptoms within several days, it is necessary to see a doctor.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
Should be careful when driving or using of the equipment.
Symptoms: – strengthening of side effects.
Treatment: – symptomatic (including the supporting measures and gastric lavage).
Futsis is brought, generally with urine therefore the artificial diuresis can accelerate drug removal.
The form of release and packing
On 4 tablets place in blister strip packaging from a film of polyvinylchloride and aluminum foil or on 1 and 4 tablets (for a dosage of 150 mg) place in blister strip packaging from a film of polyvinylchloride and aluminum foil.
On 1 blister strip packaging together with the instruction for medical use in the state and Russian languages put in a pack from cardboard.
To Store storage conditions in the place protected from light, at
a temperature not higher than 25 S. Hranit out of children’s reach!
A period of storage
According to the prescription
the Producer Kusum Heltker Pvt. Ltd.,
SP 289 (A), Riico Indl. Area, Chopanki, Bhiwadi (Raj.), India
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products (goods): Representative office of “Kusum Heltker Pvt. Ltd.” Association, India in RKg. Almaty, Dostyk Ave., 117/6, BC Khan Tengri. Phone number: 295-26-50, 295-26-51 (54), Fax: 295-26-55 e-mail address: